Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31
25 1월 2023 - 6:15AM
Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and
TSX-V: ACST), a late-stage, specialty pharma company advancing
three clinical stage drug candidates addressing rare and orphan
diseases, today announced Jan D’Alvise, CEO, will present and host
one-on-one meetings with investors at the Lytham Partners Investor
Select Conference, taking place virtually on January 31, 2023.
Company Webcast
The Company's webcast presentation will be
available for viewing at 9:00am ET on Tuesday, January 31, 2023, on
the Company's website at https://www.acasti.com/en/investors or
https://wsw.com/webcast/lytham7/acst/2032034. The webcast will also
be archived and available for replay.
1x1 Meetings
Management will be participating in virtual
one-on-one meetings throughout the event. To arrange a meeting with
management, please contact Lytham Partners at
1x1@lythampartners.com or register at
https://www.lythampartners.com/winter2023invreg/.
About Acasti
Acasti is a late-stage specialty pharma company
with drug delivery technologies and drug candidates addressing rare
and orphan diseases. Acasti’s novel drug delivery technologies have
the potential to improve the performance of currently marketed
drugs by achieving faster onset of action, enhanced efficacy,
reduced side effects, and more convenient drug delivery—all which
could help to increase treatment compliance and improve patient
outcomes. Acasti’s three lead clinical assets have each been
granted Orphan Drug Designation by the FDA, which provide the
assets with seven years of marketing exclusivity post-launch in the
United States, and additional intellectual property protection with
over 40 granted and pending patents. Acasti’s lead clinical assets
target underserved orphan diseases: (i) GTX-104, an intravenous
infusion targeting Subarachnoid Hemorrhage (SAH), a rare and life
threatening medical emergency in which bleeding occurs over the
surface of the brain in the subarachnoid space between the brain
and skull; (ii) GTX-102, an oral mucosal spray targeting
Ataxia-telangiectasia (A-T), a progressive, neurodegenerative
genetic disease that primarily affects children, causing severe
disability, and for which no treatment currently exists; and (iii)
GTX-101, a topical spray targeting Postherpetic Neuralgia (PHN), a
persistent and often debilitating neuropathic pain caused by nerve
damage from the varicella zoster virus (shingles), which may
persist for months and even years.
For more information, please visit:
https://www.acasti.com/en.
Forward-Looking Statements
Statements in this press release that are not
statements of historical or current fact constitute
“forward-looking statements” within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995, as amended, Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, and “forward-looking
information” within the meaning of Canadian securities laws
(collectively, “forward-looking statements”). Such forward looking
statements involve known and unknown risks, uncertainties, and
other unknown factors that could cause the actual results of Acasti
to be materially different from historical results or from any
future results expressed or implied by such forward-looking
statements. In addition to statements which explicitly describe
such risks and uncertainties, readers are urged to consider
statements containing the terms “believes,” “belief,” “expects,”
“intends,” “anticipates,” “estimates”, “potential,” “should,”
“may,” “will,” “plans,” “continue”, “targeted” or other similar
expressions to be uncertain and forward-looking. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press
release.
These forward-looking statements are based upon
Acasti’s current expectations and involve assumptions that may
never materialize or may prove to be incorrect. Actual results and
the timing of events could differ materially from those anticipated
in such forward-looking statements as a result of various risks and
uncertainties, including, without limitation: (i) the success and
timing of regulatory submissions of the planned Phase 3 safety
study for GTX-104 and Acasti’s other pre-clinical and clinical
trials; (ii) regulatory requirements or developments and the
outcome of meetings with the FDA; (iii) changes to clinical trial
designs and regulatory pathways; (iv) legislative, regulatory,
political and economic developments; and (v) costs associated with
Acasti’s clinical trials. The foregoing review of important factors
that could cause actual events to differ from expectations should
not be construed as exhaustive and should be read in conjunction
with statements that are included herein and elsewhere, including
the risk factors detailed in documents that have been and may be
filed by Acasti from time to time with the SEC. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Acasti undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were made.
Neither NASDAQ, the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this release.
For more information, please contact:
Acasti Contact:
Jan D’AlviseChief Executive OfficerTel:
450-686-4555Email:info@acastipharma.com www.acastipharma.com
Investor Relations:Robert BlumLytham Partners,
LLC602-889-9700ACST@lythampartners.com
Acasti Pharma (TSXV:ACST)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Acasti Pharma (TSXV:ACST)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024